Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression

Abstract Background While androgen-deprivation-therapy with the recently developed antiandrogen enzalutamide (Enz) shows promising therapeutic benefits in men with metastatic castration-resistant prostate cancer (PCa), many patients develop resistance to Enz, which may involve the induction of the a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European urology 2017-11, Vol.72 (5), p.835-844
Hauptverfasser:	Wang, Ronghao, Sun, Yin, Li, Lei, Niu, Yuanjie, Lin, Wanying, Lin, Changyi, Antonarakis, Emmanuel S, Luo, Jun, Yeh, Shuyuan, Chang, Chawnshang
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen Antagonists - pharmacology Animals Antineoplastic Agents, Phytogenic - pharmacology AR-v7 Cell Line, Tumor Curcumin - analogs & derivatives Curcumin - pharmacology Dose-Response Relationship, Drug Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Enzalutamide Gene Expression Regulation, Neoplastic Humans Malat1 Male Mice, Nude PCa Phenylthiohydantoin - analogs & derivatives Phenylthiohydantoin - pharmacology Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - genetics Prostatic Neoplasms, Castration-Resistant - metabolism Prostatic Neoplasms, Castration-Resistant - pathology Protein Isoforms Proteolysis Receptors, Androgen - metabolism RNA Interference RNA, Long Noncoding - genetics RNA, Long Noncoding - metabolism RNAi Therapeutics Time Factors Transfection Tumor Burden Urology Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!